Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Clinical trial NCT06417892 · RECRUITING
Trial details
- NCT number
- NCT06417892
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-04-15
- Primary completion
- 2027-05-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.